Next Phase Newsletter

An investment group founded by Chinese medical device experts with headquarters in China seeks to allocate 5-20 Million RMB ($0.7 – 3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel, pre-A, Series A, and B rounds. The firm seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success.

The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. The firm is also interested in investing in R&D services as well. The firm’s most recent investment was in a company that utilized AI to process images for better and faster diagnoses.

The firm heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at the firm so that they can utilize their prior experiences to help the companies grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund established by a large USA health insurer is seeking to develop a portfolio of investments that, as a whole, focus on improving the national health care market, enhance the core business of the company and generate revenue.

These strategic investments are expected to be integrated into the company as part of its overall long-term strategy. The firm prefers to syndicate with a strong lead investor in a financing round and expects to make 5 – 7 new investments of $0.5-2 million in the coming year. The firm considers opportunities across the US and around the world with preference given to companies in the middle of the country.

The firm is interested in digital health technologies and care delivery models that can improve healthcare. The firm prefers products with prototype and customer traction.

The firm would like to be a strategic partner, as a payer, for startups. The firm prefers early stage teams backed by experienced management, supported by reputable early stage VC and/or angel groups that have a history of follow-on investments in Series A and B.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the Bay area has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. The firm continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in Seed to Series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund based in the East Coast leads investments in high growth, mostly US-based digital health, SaaS, PaaS and technology-enabled service businesses. The firm has a flexible model to right-size equity investments with initial investments typically in the range of $1M to $10M. The firm is active in governance and seeks to remain involved through multiple financing rounds. The fund targets a 5-year investment window.

The fund’s investments are focused on a few key themes in businesses that improve the human condition and deliver value-based care. It seeks investments in B2B or B2B2C companies with proven business models and experienced teams pursuing end-market opportunities large enough to support creation of companies with $1B in enterprise value. Thematic areas of focus include personalized medicine, patient navigation, referral management, and enablement of payer-provider risk sharing.

The firm is open to working with management teams with various levels of experience. The fund does seek a board seat along with investment and prefers to be fairly involved with the management team and strategy of the company. The fund does not purchase secondary shares of a company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A specialized USA venture capital firm under a large Chinese holding company has headquarters in Shanghai, China and an additional virtual office in the USA. The firm is actively seeking investment opportunities from early-stage to pre-IPO rounds.  The average size of investment is around $5M. The firm has invested in 17 US & Canada companies since 2016.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies. The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA.  The firm is open to medical devices and therapeutics in any stage of development. However, the firm will invest in private companies only.

The firm has no specific requests on the management team. The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm based in the USA has a newly established venture capital strategy, which has a specific focus in early-stage, pre-revenue biotech companies. The firm’s initial investment is usually around $500K, but the firm has invested as low as $250K and as high as $2-3M. At present, the firm is primarily looking for USA-based opportunities with a focus on the Midwest and East Coast regions.

The firm invests broadly across early-stage therapeutics, medical devices, and diagnostics. The firm is most interested in technologies with strong intellectual property. The firm is open to investing in all classes of medical devices including 510k and PMA. The firm works closely with a group of scientists who covers a wide range of expertise including cancer diagnostics, immunotherapy, diseases of the ear and eye, etc. The firm is not interested in healthcare analytics companies.

The firm is flexible and is open to working with all different kinds of management teams, though experience and a successful track record is a plus. The firm has both led and co-invested in financing rounds and seeks board representation most of the time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices in the USA and Europe is currently investing from the firm’s newest $585 million venture fund. The firm is open to investment opportunities globally.

The firm is currently interested in novel concepts and platforms across the life sciences. The firm invests in therapeutics, devices and diagnostics, and has a lesser interest in technology-led companies in the healthcare IT space (the firm is not interested in service-based/SaaS healthcare IT businesses). The firm prefers early stage opportunities; in therapeutics, the firm focuses on pre-IND technologies.

While the firm invests across many areas, one focus at present is immunology assets that aim to treat infectious diseases (viral and bacterial), with a focus on immune priming or changing the immune system. Any immunological therapeutic modality is of interest, including vaccines. The firm is interested in reviewing immunology assets at any stage of development.

The firm only invests in privately held companies that have not previously raised a Series A round or a significant seed round. The firm is a highly hands-on, active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.